Vivos Therapeutics, Inc. (VVOS)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 3,820 | 3,016 | 3,860 | 4,054 |
| Cost of sales (exclusive of depreciation and amortization shown separately below) | 1,710 | 1,507 | 1,526 | 1,403 |
| Gross profit | 2,110 | 1,509 | 2,334 | 2,651 |
| Sales and marketing | 260 | 358 | 346 | 320 |
| General and administrative | 6,409 | 4,892 | 4,487 | 4,122 |
| Depreciation and amortization | 306 | 177 | 146 | 145 |
| Total operating expenses | 6,975 | 5,427 | 4,979 | 4,587 |
| Operating loss | -4,865 | -3,918 | -2,645 | -1,936 |
| Other income | 15 | 58 | 47 | 28 |
| Other expense | -163 | -4 | -18 | -22 |
| Loss before income taxes | -5,013 | -3,864 | -2,616 | -1,930 |
| Net loss | -5,013 | -3,864 | -2,616 | -1,930 |
| Net loss per share (basic) | -0.55 | -0.45 | -0.4 | -0.6 |
| Net loss per share (diluted) | -0.55 | -0.45 | -0.4 | -0.6 |
| Weighted average number of shares of common stock outstanding (basic) | 9,087,202 | 8,595,288 | 6,615,320 | 3,228,363 |
| Weighted average number of shares of common stock outstanding (diluted) | 9,087,202 | 8,595,288 | 6,615,320 | 3,228,363 |